$3.96
-0.17 (-4.12%)
Open$4.10
Previous Close$4.13
Day High$4.15
Day Low$3.93
52W High$5.55
52W Low$2.65
Volume—
Avg Volume552.3K
Market Cap208.15M
P/E Ratio—
EPS$-2.16
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+1,072.7% upside
Current
$3.96
$3.96
Target
$46.44
$46.44
$29.94
$46.44 avg
$64.67
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 67.95M | 52.73M | 42.57M |
| Net Income | -55,206,702 | -38,561,142 | -129,666 |
| Profit Margin | -81.3% | -77.2% | -0.3% |
| EBITDA | -66,187,311 | -48,799,336 | -158,434 |
| Free Cash Flow | — | — | -114,389 |
| Rev Growth | +28.9% | +28.9% | +21.1% |
| Debt/Equity | — | — | 0.31 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.03 | -0.25% | 139.7 | 43.84B |